Management

Juan J. Pérez Villar, PhD. CEO, holds a MS degree in Biochemistry and a PhD in Immunology and Inflammation from the Autónoma University of Madrid (UAM), developed an extensive international career in the biopharmaceutical industry in drug discovery and business development. Previously, was the business development managing partner at Biolty (Madrid, Spain) a biopharma consultancy; group head of oncology at Agensys / Astellas Inc. (Santa Monica, CA, USA) and Bristol-Myers Squibb Co. (Princeton, NJ, USA). Juan participated in pre-clinical development of biologics such as abatacept/Orencia® and belatacept/Nulojix® both modulators of the CD28 co-stimulatory activity for inflammation and transplantation; the AGS-PSCA mAb in advanced pancreatic cancers and the small molecule dasatinib (Sprycel®), a multiple tyrosine kinase inhibitor for chronic myeloid leukemia; additionally, he is the inventor of numerous granted patents in the USA and Europe and peer reviewed publications. Previously, he participated in fund-raising activities for a venture capital fund and the launching of a cancer therapeutic vaccine company.
 
Marta Compte Grau, MD, PhD. I+D Director. Marta attended medical school at Navarra University (Pamplona, Spain) and Hospital Universitario Puerta de Hierro where completed her residency in Immunology; soon after, attended the Molecular Medicine Program at the Mayo Clinic (Rochester, MN, USA) where she worked with Richard Vile in the development of novel cancer immunology strategies. Further, she earned a PhD in Immunology from the Autónoma University of Madrid (UAM). Marta has extensive experience in antibody engineering and development of gene and cellular immunotherapeutic strategies against cancer based on recombinant bispecific antibodies. 

Latest News

Leadartis announces the publication "An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research
02-04-2021
Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models
13-01-2021

Leadartis reaches a major milestone with the demonstration of...

Leadartis featured in EXPANSION as a ‘Start up’ that leads the fight against cancer
10-11-2020

...